DoW Duchenne Muscular Dystrophy, Idea Development Award | Apply Online

FY26 Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) - FAQs

What is the FY26 DMDRP Idea Development Award (IDA)?

The FY26 Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) is a U.S. Department of Defense-sponsored grant opportunity (administered through the Defense Health Agency contracting activity) that supports new, early-stage research ideas in Duchenne muscular dystrophy (DMD). The award is intended to move innovative concepts forward by generating meaningful, actionable data that can accelerate progress toward better outcomes for people living with DMD.

What is the main purpose of this award?

The central purpose is to fund high-risk, high-reward projects that are scientifically well grounded but not yet fully mature. The IDA is meant to help open new research directions or enable discoveries that can speed near-term progress in DMD research.

What kinds of projects is the program trying to fund?

The program is looking for innovative, early development work that is positioned to produce actionable data. While early-stage and bold ideas are encouraged, the work should still be feasible and supported by evidence directly relevant to DMD.

Does the IDA emphasize innovation or feasibility?

Both. The emphasis is on innovation and early development, but applications are expected to show feasibility through preliminary data and a strong scientific rationale. The program’s intent is to support well-justified risk, rather than unsupported speculation.

Is a hypothesis required?

Yes. Proposed projects are expected to be built around a clear, testable hypothesis supported by a strong scientific rationale.

Is preliminary data required?

Yes. Although the award is designed for early-stage ideas, the program still requires preliminary data that is directly relevant to DMD and demonstrates feasibility of the hypothesis and approach.

What does "high-risk, high-reward" mean in the context of this opportunity?

It means the program is interested in bold research ideas that could materially move the field forward, even if outcomes are uncertain, as long as the concept is scientifically well grounded and supported by relevant preliminary data that helps justify the risk.

Are clinical trials allowed under this award?

No. Clinical trials are not allowed under this mechanism.

Can an application include clinical trial aims?

No. Proposals cannot include clinical trial aims, making this award best suited for preclinical research, translational groundwork, or other non-trial research activities that can de-risk and justify future clinical testing under other mechanisms.

What stage of research is this award best suited for?

Based on the restrictions described, the award is best suited for preclinical work, translational groundwork, and other non-clinical-trial research that can generate the data needed to support and justify later clinical testing through other funding opportunities.

Is there a special focus on therapies that work across different stages of DMD?

Yes. A notable priority is therapeutic research that can demonstrate efficacy across the lifespan of individuals with DMD, signaling interest in approaches that are not limited to a single disease stage.

Does the solicitation encourage inclusion of underrepresented DMD populations?

Yes. The announcement explicitly highlights the importance of considering populations that are sometimes underrepresented in study designs, including infants and toddlers as well as nonambulatory individuals.

Does this mean projects must focus on infants/toddlers or nonambulatory individuals?

The information provided describes this as an explicit priority and encouragement. It indicates strong interest in approaches that can realistically help patients at different points in disease progression, including those groups.

How is the IDA structured in terms of applicant categories?

The IDA mechanism is structured around three applicant career categories: Established Investigator, New Investigator - Early-Stage, and New Investigator - Transitioning. Each category has its own review context.

Who qualifies as an Established Investigator for this award?

The Established Investigator category is open to independent investigators at any academic rank (or equivalent).

Who qualifies as a New Investigator - Early-Stage?

This category is for independent investigators within 10 years of their first faculty appointment (or equivalent). Applications in this group are reviewed separately from established investigators.

Who qualifies as a New Investigator - Transitioning?

This category is for independent investigators who are established in a field outside muscular dystrophy and want to pivot into DMD research by bringing expertise from another discipline. These applications are also reviewed separately from established investigators.

Are New Investigator applications reviewed together with Established Investigator applications?

No. The information provided states that New Investigator - Early-Stage applications are reviewed separately from established investigators, and New Investigator - Transitioning applications are also reviewed separately from established investigators.

Who is eligible to apply?

Eligible applicants are described as unrestricted, meaning the opportunity is broadly open rather than limited to a narrow set of institution types.

What agency sponsors this opportunity?

The opportunity is U.S. Department of Defense-sponsored and is administered through the Defense Health Agency contracting activity.

What is the funding opportunity number?

The funding opportunity number is HT942526DMDRPIDA.

What is the CFDA number and program area?

The opportunity is listed under CFDA 12.420 and falls within the science and technology/research and development area.

How many awards are expected?

The posting indicates an expected number of awards of 5.

What is the application closing date?

The original closing date is September 18, 2026.

What is the overall emphasis of the DMDRP IDA in DMD research?

The overall emphasis is on advancing innovative, early-stage DMD research that is hypothesis-driven, supported by DMD-relevant preliminary data, and capable of generating actionable results. The solicitation also highlights interest in therapeutic approaches with potential across the lifespan, including underrepresented patient groups such as infants/toddlers and nonambulatory individuals.